Work

ABCL-482 Five-Year Subgroup Analysis of Tafasitamab + Lenalidomide From the Phase II L-MIND Study in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Year: 2023

Type: article

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(23)01327-7

Authors: Johannes Duell, Pau Abrisqueta, Martin Dreyling, Gianluca Gaidano, Eva González Barca, Wojciech Jurczak, Kami J Maddocks, Tobias Menne, Zsolt Nagy, Olivier Tournilhac, Abhishek Bakuli, Aasim Amin, Konstantin Gurbanov, Gilles Salles

Institutions: University of Würzburg, Universitätsklinikum Würzburg, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Ludwig-Maximilians-Universität München, Università degli Studi del Piemonte Orientale “Amedeo Avogadro”, Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia, Duran i Reynals Hospital, Universitat de Barcelona, The Maria Sklodowska-Curie National Research Institute of Oncology, The Ohio State University Wexner Medical Center, The Ohio State University, Freeman Hospital, Semmelweis University, Centre Hospitalier Universitaire de Clermont-Ferrand, MorphoSys (Germany), Memorial Sloan Kettering Cancer Center

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4386281972

FWCI:

Cites:

Cited by:

Related to: 10